High-affinity antibody production, T cell activation, and Interferon upregulation all contribute to protective immunity that occurs in humans following influenza immunization. Hematopoietic cell-specific PTPN22 encodes Lymphoid Phosphatase (Lyp), which regulates lymphocyte antigen receptor and Pattern Recognition Receptor (PRR) signaling. A PTPN22 variant R620W (LypW) predisposes to autoimmune and infectious disease, and confers altered signaling through antigen receptors and PRRs.
Introduction
Influenza virus infection poses a substantial public health burden, resulting in approximately 200,000 hospitalizations and between 7,505 to 37,102 deaths annually in the U.S. (1, 2) . Annual influenza vaccination can provide protection against circulating seasonal strains, provided there is good matching between viral vaccine strains and circulating strains (3) (4) (5) .
Protective immunity to influenza virus results from combined humoral and cellular immune responses. Neutralizing antibodies can provide sterilizing immunity to homologous viral strains by preventing viral attachment and entry to host epithelial cells (6) . Antibody neutralizing capacity is heavily dependent upon specificity and epitope binding affinity (7) . However, due to high mutation rates in influenza genes encoding hemagglutinin (HA) and neuraminidase (NA) proteins, most neutralizing antibodies elicited by vaccination are strain-specific and often do not provide heterosubtypic immunity (8, 9) .
T cells are important cellular effectors of antiviral immunity. CD8 T cells mediate direct lysis of infected epithelial cells (10) , and high levels of virus-specific CD8 T cells correlate with lower viral shedding and lower disease severity in humans (11, 12) . CD4 T cells contribute to anti-viral immunity by providing help to B cells for efficient isotypeswitching (13) and affinity maturation (14) needed in the generation of virus-specific antibodies (15) , and by providing help to CD8 T cells (16) . CD4 T cells can also secrete IFNγ in the lungs (17) , and can directly lyse virus-infected, MHC-II-expressing bronchial A c c e p t e d M a n u s c r i p t 5 epithelial cells in a perforin-dependent manner (18) . Both CD8 and CD4 T cells are strongly implicated in heterosubtypic immunity to influenza, due to their recognition of viral proteins that are largely conserved across strains (11, (18) (19) (20) .
In addition to stimulating adaptive responses, influenza infection or vaccination can induce transcription of numerous interferon (IFN)-regulated genes (21, 22 ). An early IFN signature correlates with B cell responsiveness to vaccination and the development of neutralizing antibodies, suggesting that IFN signaling plays a role in anti-influenza antibody production (23) . Indeed, in animals, type I IFN are critical for generation of both protective antibody and CD4 T cell responses to influenza vaccination (24) . The requirements for type I IFN and innate immunity in vaccine-induced protective immunity among humans remain incompletely defined.
Protein Tyrosine Phosphatase Non-receptor 22 (PTPN22) encodes Lymphoid Phosphatase (Lyp), a hematopoietic-specific intracellular protein. Lyp functions as a negative regulator of TCR signaling (25) , and positively modulates interferogenic Tolllike Receptor (TLR) signaling in macrophages and dendritic cells (26, 27) . A human PTPN22 coding polymorphism, C1858T, associates with significantly increased risk of numerous autoimmune diseases, including rheumatoid arthritis, systemic lupus erythematosus, type 1 diabetes, and with altered susceptibility to selected Grampositive and mycobacterial infections (28) (29) (30) . C1858T is carried by 6-9% of persons of European ancestry (31) . C1858T encodes a single amino acid substitution-bearing A c c e p t e d M a n u s c r i p t 6 (R620W) protein variant, termed LypW, that exhibits altered function in TCR signaling and in TLR-driven type I IFN production .
To date, studies testing LypW function in primary human lymphocyte and innate immune cell responses have utilized in vitro or ex vivo approaches (32) (33) (34) (35) (36) (37) (38) . Information concerning the role of human LypW during immunization responses has not been reported. Since PTPN22 regulates both lymphocyte and innate immune cell signaling and activation, we tested the hypothesis that R620W carriers would mount diminished or defective innate, cellular and humoral responses to influenza vaccination.
Methods:

Subject recruitment and sample collection
Healthy adult volunteers submitted DNA for PTPN22 rs2476601 (C1858T) genotyping.
PTPN22
LypW carriers (heterozygote n=17; homozygote n=1) and age and sexmatched non-carriers (LypR, n=17) received intramuscular Fluzone (2013-2014 trivalent inactivated influenza vaccine (TIV); Sanofi Pasteur). Subjects submitted blood prevaccine, and at days 1, 14-15, and 25-28 following vaccination. IRB approval was obtained (University of Minnesota, protocol #1210M21901), and all subjects provided informed written consent.
Genotyping
DNA was extracted from participant blood using the DNeasy Blood & Tissue kit (Qiagen), and subjects were genotoyped for the PTPN22-C1858T SNP by Taqman A c c e p t e d M a n u s c r i p t 7 assay (Applied Biosystems). HLA-A genotype was determined by BLAST analysis of sequenced HLA-A PCR amplicons (39) using the IMGT/HLA database (https://www.ebi.ac.uk/ipd/imgt/hla/).
Hemagglutination inhibition assay:
Serum was mixed with Aprotinin (Sigma) before freezing. Hemagglutination inhibition assays (HAI) were performed using the WHO 2013-2014 Influenza Reagent Kit and Turkey RBCs in Alsevers (Colorado Serum) according to manufacturer's instructions.
Biolayer Interferometry Assay of Human Serum Samples
Real time binding assays of antibodies in human sera and purified hemagglutinin proteins were performed using biolayer interferometry with an Octet RED system (ForteBio, Inc.). Human sera were heated at 56° for 30min before the assay. 
CD4 T cell assessments:
PBMC were isolated from whole blood, and stored at -80 °C until batched analysis.
Thawed PBMCs were washed with complete pre-warmed RPMI 1640. Cells were rested before stimulating 6 hours in the presence of Brefeldin A (eBioscience) with either 2013-2014 Fluzone (10 uL), PMA (50ng/ml) and ionomycin (1ug/mL; Sigma), or medium alone. Cells were stained with fixable viability dye and surface antibodies (see supplement) before permeabilization and intracellular staining. Data were acquired on an LSRFortessa (BD), and were analyzed using FlowJo software (Tree Star). CD4 T cells were gated as shown in Supplementary Fig. 4 . The influenza-specific CD4 T cell fraction was calculated by subtracting numbers of cytokine-positive events observed in no-stimulation control from total cytokine-producing events observed in Fluzone stimulated conditions.
Statistical Analysis:
Chi-square test was used to compare categorical variables of antibody seroconversion and seroprotection. The Student's T-test was used to compare antibody titers, isotype and affinity; CD4 and CD8 T cell frequency; and costimulatory molecule MFIs between groups. Within-group baseline and post-vaccination values were compared using a paired T-test. The Mann-Whitney test was also performed as an alternative nonparametric test. For transcriptional analyses, Mann-Whitney test was performed for A c c e p t e d M a n u s c r i p t 9 each gene to compare the expression levels between groups, followed by a gene-set enrichment association test (GSEA) (40) with 10,000 permutations. Bonferroni correction was used for multiple testing. Statistical analysis was performed using Stata (version 13.1, StataCorp) and GraphPad Prism 5 software.
For additional methods, refer to supplementary material.
Results:
LypW carriage associates with poor antibody affinity maturation after TIV
To examine the role of PTPN22 R620W variant (LypW) in human in vivo responses to influenza vaccination, we immunized healthy LypW carriers (n=18) or non-carriers (n=17; Table 1 shows subject characteristics) with TIV. First, we compared trivalent inactivated influenza vaccination (TIV)-induced antibody levels in LypW carriers and non-carriers. We found that pre-vaccine seroprotection, defined as hemagglutination inhibition (HAI) titer ≥1:40, was present in 82-100% of subjects (Table 2) . These results suggested high rates of previous vaccination or infection. 25 days after vaccination, the majority of subjects exhibited significant increases in mean neutralizing antibody titers for H1N1 and H3N2 (Fig. 1A) . However, we noted no statistically significant differences between LypW carriers and non-carriers (LypR) in average absolute HAI titers, in rates of seroconversion (defined as fold-increase in neutralizing titer ≥4), or in rates of seroprotection (100%) after TIV vaccination (Table 2) .
A c c e p t e d M a n u s c r i p t 10 Antibody isotype switching and affinity maturation are important for development of a neutralizing anti-influenza antibody repertoire (7). To assess immunization-induced isotype switching, we measured serum levels of IgM, IgG and IgA specific for H1N1 HA.
LypW carriers and non-carriers showed equivalent enhancement of IgG and IgA anti-HA in response to vaccination (Fig 1B, supplementary Fig. 1 ). However, mean anti-HA IgM levels in LypW carriers were significantly higher than levels in LypR subjects at baseline (Fig. 1C) . We also assessed the role of LypW in antibody affinity maturation during the influenza response. Biolayer interferometry was used to measure the dissociation constants (affinity) of serum antibodies against H1N1 HA. While serum from LypR noncarrier subjects displayed a significant increase in anti-HA binding affinity (mean 2.6-fold) after vaccination, LypW carrier serum did not (Fig. 1D, supplementary Table 1 ).
Together, these results suggested that LypW carriage associates with increased IgM anti-HA antibodies, and with altered capacity to form high-affinity antibody to TIV.
LypW carriers show diminished CD4 T cell responses to TIV
CD4 T cell help is critical for optimal isotype switching and affinity maturation (13, 14) .
To study the role of LypW in CD4 T cell immunization responses, we exposed PBMC from immunized subjects to TIV in vitro. Vaccine-stimulated CD4 T cell production of any of three cytokines−IFNγ, TNFα, or IL-2−was used as an indicator of influenza specificity (41) (Fig. 2A) . Unstimulated and PMA/Ionomycin stimulated CD4 T cells were used as negative and positive controls for cytokine production, respectively, and no difference between LypR and LypW subjects was detected in either of these stimulation conditions (supplementary Table 2 ). Frequency of influenza-specific CD4 T cells among A c c e p t e d M a n u s c r i p t 11 PBMC increased in LypR (non-carrier) subjects 2 weeks post-vaccination (Fig. 2B,C) .
However, LypW carriers showed no vaccination-induced increase in the frequency of influenza-specific CD4 T cells, either by analysis of pooled cytokine-producers (Fig. 2C) , or of CD4 T cells producing individual cytokines (Supplementary Fig. 2) . A similar pattern was seen with enumeration of absolute numbers of TIV-specific CD4 T cells (supplementary Figure 3) . Geometric mean fold-change increase in TIV-induced influenza-specific CD4 T cells among non-carriers was 2.6 (95% C.I. 2.019-3.426), compared to 1.3 among LypW carriers (95% C.I. 0.926-2.018)( + ) increased significantly in non-carrier LypR subjects, but not in LypW carriers. These data suggested that LypW carrier CD4 T cells might be subject to impaired TCR-dependent priming (Fig. 3A) . We observed no alteration in expression of PD1, a marker for dampened T cell responsiveness, in either basal or vaccine-induced influenza-specific CD4 T cells between LypR and LypW carriers (Fig 3B) . We observed no differences in responder T cell polyfunctionality (42) between non-carriers and LypW carriers, as the fractions of influenza-specific CD4 T cells expressing single or multiple cytokines were unchanged by vaccination or genotype (Fig. 3C) . Together, these findings suggest that LypW carriage confers reduced capacity for TIV-induced expansion and activation of CD4 T cells, but that restricted T cell expansion is not a result of increased PD1 expression in LypW carrier T cells.
A c c e p t e d M a n u s c r i p t 12
LypW carriage does not affect TIV induction of costimulatory molecules
Antigen presenting cell (APC) activation and interferon signaling represent T cellextrinsic factors that enhance CD4 responses to immunization (24, 26) . PTPN22
variants differentially modulate these processes in animals (26, 43) ; therefore, we investigated potential roles for LypW in human T cell-extrinsic immunization responses.
Optimal T cell activation and clonal expansion depend upon costimulatory signals delivered through CD86 and CD40 expressed on APC (44, 45 Figure 5 ) (21). We found that TIV induced significant upregulation of CD40 expression on monocytes, CD123 + CD11c + DCs, and pDCs (Fig. 4A) , and drove upregulation of CD86 on pDC (Fig.   4B ). However, LypW carriers and non-carriers showed no difference in co-stimulatory molecule upregulation. Additionally, myeloid cell subsets from LypR and LypW carrier subjects showed no difference in upregulation of CD86 (supplementary Table 3 
TIV does not impact peripheral blood CD8 T cell numbers or function
In animals, Ptpn22 deficiency is associated with decreased expansion of virus-specific CD8 T cells after RNA viral infection (26) . We assessed the role of LypW carriage in expansion of human antigen-specific CD8 T cells after TIV immunization. We used tetramers to determine frequency of influenza-specific CD8 T cells among PBMC in those vaccine recipients found to harbor MHC Class I HLA-A*02 (LypR n=9; LypW n=8).
We observed no vaccine-inducible change in the frequency of influenza-specific CD8 T cells two weeks after TIV in either LypR or LypW subjects (Fig. 5A) . Moreover, neither A c c e p t e d M a n u s c r i p t 14 group showed evidence of vaccine-inducible increases in influenza-specific CD8 T cell proliferation, activation state, or development of effector function, as detected by upregulation of Ki-67 (Fig. 5B) , by change in frequency of CD38 + HLA-DR + (Fig. 5C ), or by expression of Granzyme B (Fig. 5D ), respectively. These data strongly suggest that seasonal TIV does not induce detectable expansion or activation of peripheral blood influenza-specific CD8 T cells at two weeks following TIV. The data do not permit conclusions about a potential role for LypW in human CD8 responses to vaccine.
Discussion:
This study addresses PTPN22 variant LypW effects on human immune responses induced in vivo. After TIV vaccination, we found that LypW carriers exhibit markedly impaired influenza-specific CD4 T cell expansion, and show no significant increase in anti-influenza antibody affinity, compared to LypR (non-carrier) subjects. While both LypR and LypW subjects show equal induction of isotype-switched antibodies against HA, LypW carriers harbor significantly higher HA-specific IgM titers at baseline and after vaccination. The immunological implication of our findings is that human LypW carriage results in multiple alterations in adaptive immune responses to anti-viral immunization.
Our results also have potential clinical significance. Since numbers of influenza-specific CD4 T cells correlate with protection against influenza infection (18, 46) , and since high affinity anti-influenza antibodies associate with reduced viral titers after infection (7), the reduced CD4 T cell expansion and impaired affinity maturation observed in LypW carriers could translate to increased vulnerability to influenza infection following vaccination (18, 46) . One important caveat to our findings is the small sample size of this Animal studies have explored roles of PTPN22 variants in immunization responses.
Early observations in Ptpn22-deficient mice suggested a T cell-intrinsic effect of Ptpn22 in restraining T cell expansion to peptide immunization (36) . Two groups have studied animals bearing knockins for Ptpn22-R619W, a murine LypW orthologue (49,50).
R619W-expressing T cells produce more antigen-stimulated IL-2 following
OVA/adjuvant immunization (49) . Further, R619W knockin mice show increased antibody titers against T-dependent antigens after adjuvanted peptide immunization (49, 50) . Together, these data argued that in mice, Ptpn22 functions to repress immunization-induced T cell expansion/activation and that R619W is a loss of function variant in T cell vaccination responses.
Multiple factors could contribute to apparent discordance between the above-described animal study results and our finding of diminished CD4 expansion in TIV-exposed human LypW carriers. First, T cell responses in naïve, syngeneic mice may differ from those elicited in antigen-experienced, outbred humans. Second, the present study documents human responses to a non-adjuvanted "split" viral protein preparation, Therefore we were surprised that we detected no LypW-dependent alterations in APC activation after TIV exposure in the present study (Fig. 4) . However, interpretation of A c c e p t e d M a n u s c r i p t
